Excellence is just the beginning.


French German Italian Portuguese Russian

Genitourinary Cancer Services — Clinical Trials

High Risk Prostate Cancer Hormone and Radiation Therapy Treatment Study

Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: A phase III randomized trial.

High-Risk Biochemically Relapsed Prostate Cancer Treatment Study

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Treatment Study

Phase Ib/II trial of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-365).

Metastatic Hormone Sensitive Prostate Cancer Therapy Study

Study to determine if subjects with mHSPC will benefit from the addition of apalutamide to ADT.

Prostate Cancer Study

Phase 3, double blind trial, using investigational product in asymptomatic subjects with Gleason sum equal to or lesser than 7, metastatic androgen independent prostatic adenocarcinoma

Radiation Therapy Treatment Study for Stage III-IV Prostate Cancer

A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer.

SBRT for Localized Prostate Cancer Study

A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.

Study of Standard Systemic Therapy in Treating Prostate Cancer

Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.

Treatment Study for Patients with Metastatic Castration Resistant Prostate Cancer

A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide or abiraterone/prednisone in patients with metastatic castration resistant prostate cancer.

Treatment Study for Patients with Prostate Cancer

Phase II-III trial of adjuvant radiotherapy following radical prostatectomy with or without adjuvant docetaxel.